
    
      Approximately 146 patients will be enrolled in this study. Each patient will receive 1
      injection and be evaluated for efficacy and safety during a 12-month observation period. The
      study is expected to be completed within 36 months, inclusive of enrollment and follow-up of
      all subjects.
    
  